Pfizer vaccine booster highly effective in late-stage trial

A booster of Pfizer-BioNTech’s COVID-19 vaccine has proved highly effective in warding off disease from the dominant delta strain of the coronavirus, according to preliminary results of a late-stage trial.  The booster dose was 95.6% at preventing disease, compared to those who didn’t receive an extra shot in ... haber ile ilgili daha fazla detay okumak için, more news Pfizer vaccine booster highly effective in late-stage trial